MIAT

What MIAT does

MIAT S.p.A. is an Italian privately-held pharmaceutical trading and distribution company founded in 1984 and headquartered in Milan. The company positions itself as a "business bridge between East and West," trading Active Pharmaceutical Ingredients (APIs), intermediates, finished pharmaceutical products, medical devices, and nutraceutical ingredients across 51 countries, with deep supplier relationships in Korea and Japan spanning 30-40 years. The portfolio includes 400+ APIs (with hyaluronic acid as a historic flagship), patented devices such as the ANDI-MED nebulizing chamber (European Patent No. 13783105.3) and the MIAT-Haler dry powder inhaler (via Andi-Ventis JV with Medochemie in Cyprus), and exclusive worldwide distribution rights (ex-Japan) for Nipro's NP-CONTAINER ophthalmic container.

MIAT operates a dual trading-plus-light-manufacturing business model. Revenue is generated through (a) markup-based distribution of APIs, intermediates, and finished products to pharmaceutical manufacturers, and (b) contract manufacturing and in-licensing distribution of specialty pharmaceutical products (including medicated plasters) enabled by AIFA-issued GMP certifications. The company maintains a GMP-certified controlled-temperature warehouse (18°C with refrigerated cell at 5°C±3) at its Milan facility and holds ISO 9001:2015, ISO 13485, GMP, and GDP certifications, providing end-to-end regulatory support including DMF registration, e-CTD submissions, and CE/PIF marking.

The go-to-market is relationship-driven B2B enterprise field sales, with major industry exhibitions (CPHI since 1989, IMCAS World Congress since 2026) serving as primary customer acquisition channels. Customer segments span pharmaceutical, nutraceutical, medical device, and cosmeceutical companies. In July 2025, MIAT launched a Nutritional Solutions division targeting functional nutrition, and maintains an early-stage oncology pipeline (s-4-oxo-HPR) developed with Fondazione IRCCS Istituto Nazionale dei Tumori. Cross-shareholding with Korean partner SAM-OH Pharm (since 2016) and joint ventures with Medochemie anchor the company's ecosystem.

Name

MIAT

Legal name

MIAT S.p.A.

Website

https://miat.it

Company type

Private

Founded year

1984

Operating status

Operating

Headcount range

11–50 employees

Short description

MIAT S.p.A. is an Italian privately-held B2B pharmaceutical trading company founded in 1984, bridging Western and Asian markets by distributing 400+ APIs, intermediates, medical devices, and finished pharmaceutical products across 51 countries, with GMP-certified warehousing and patented respiratory delivery devices.

Ownership category

akta.pro rank

Product category

Pharmaceutical Distribution & Trading

NAICS

Drugs and Druggists' Sundries Merchant Wholesalers (424210), Warehousing and Storage (493)

SIC

Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Pharmaceutical & Biopharma Cold Chain Logistics (2–8°C, CRT, GDP) (TLAIAIAA)

akta.pro secondary industries

Pharmaceutical & Life Sciences Warehousing (GDP-Compliant) (TLAIACAD), Medical Devices & Diagnostics (TLAIALAD)

Keywords

• Pharmaceutical trading
• Active pharmaceutical ingredients
• Pharmaceutical intermediates supply
• Medical device distribution
• Nutraceutical ingredient supply

Headquarters

HQ city

Milano

HQ country

Italy

HQ region

Europe

Offices3 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Operations, Personnel, Marketing or Sales, Technology or R&D, Supply Chain

Revenue model

1. Pharmaceutical Trading and Distribution: MIAT trades intermediates, active pharmaceutical ingredients (APIs), nutraceutical products, medical devices, and pharmaceutical finished products. Revenue generated through markups on procurement and distribution of pharmaceutical raw materials and finished products across international markets.
2. Contract Manufacturing and Production: Following GMP certification, MIAT obtained authorization for pharmaceutical workshop operations, enabling production and in-licensing distribution of Specialties/Special Pharmaceutical Products in different territories, including medicated plasters.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Core offering

MIAT S.p.A. is a B2B pharmaceutical trading and distribution company that sources, supplies, and distributes Active Pharmaceutical Ingredients (APIs), pharmaceutical intermediates, finished pharmaceutical products, medical devices (respiratory, ophthalmic, dermatological), nutraceutical ingredients, and specialty pharmaceutical products. The company also operates a GMP-certified pharmaceutical workshop for contract manufacturing and in-licensing distribution, and provides regulatory support (DMF registration, e-CTD submissions) along with GDP-compliant cold-chain logistics from its controlled-temperature warehouse in Milan.

Product overview

MIAT S.p.A. is an Italian pharmaceutical trading company acting as a 'business bridge between East and West.' Its product portfolio spans five core product categories: (1) APIs — including hyaluronic acid, antibiotics, steroids, biological products, and nutraceuticals; (2) Medical Devices — respiratory devices (nebulizers, MIAT-Haler inhaler), ophthalmic products (NP-CONTAINER), and dermatological products (plasters, gel patches); (3) Specialties/Special Pharmaceutical Products — authorized as a pharmaceutical workshop for production and in-licensing distribution; (4) Intermediates — non-natural amino acids, chiral intermediates, and side chains for API manufacturers; and (5) HPLC Columns — analytical products from partner RStech. Additionally, the 2025-launched Nutritional Solutions division extends MIAT into functional nutrition with high-purity ingredients and over 80 botanical extracts targeting cognitive, immune, metabolic, anti-aging, psycho-physical, and joint/bone health applications. MIAT's pipeline includes s-4-oxo-HPR, a patented cancer therapeutic candidate developed with Fondazione IRCCS Istituto Nazionale dei Tumori.

Differentiator

Problem solved

Functional benefit

Products and services

• Active Pharmaceutical Ingredients (APIs) Portfolio of 400+ Active Pharmaceutical Ingredients sourced from qualified international suppliers, including pharmaceutical-grade hyaluronic acid (MIAT's historic product), antibiotics, steroids, corticosteroids, biological products, and nutraceutical ingredients. AIFA Import Authorization covers extra-EU APIs. Targeted at pharmaceutical manufacturers.
• Medical Devices Innovative medical devices across three therapeutic areas: respiratory (nebulizers, dry powder inhalers including the patented MIAT-Haler, ANDI-MED nebulizing chamber), ophthalmic (Nipro NP-CONTAINER multidose preservative-free containers), and dermatological (medicated plasters, hydrogel gel patches). Includes CE marking and PIF regulatory support.
• Specialties / Special Pharmaceutical Products Pharmaceutical workshop offering production and in-licensing distribution of special pharmaceutical products covering pain treatment, ophthalmology, and respiratory therapeutic areas. Operates under AIFA GMP certification for contract manufacturing.
• Pharmaceutical Intermediates Supply of specific intermediates including non-natural amino acids and derivatives, chiral intermediates, and side chains developed for API producers. Targeted at pharmaceutical manufacturers requiring building blocks for active ingredient synthesis.
• HPLC Columns Analytical HPLC columns sourced from Korean partner RStech Corporation, providing a wide range of chromatographic analysis products for pharmaceutical quality control laboratories.
• Nutritional Solutions Dedicated business unit offering high-purity, scientifically supported nutritional ingredients across six health areas (cognitive, immune/gut, metabolic, anti-aging, psycho-physical, joint/bone) plus over 80 botanical extracts. Targeted at nutraceutical, functional food, and dietary supplement manufacturers.
• NP-CONTAINER (Nipro) High-technology multidose preservative-free container for ophthalmic formulations, distributed worldwide (excluding Japan) by MIAT under agreement with Nipro Corporation (Japan). Targeted at ophthalmic pharmaceutical companies.
• MIAT-Haler (Dry Powder Inhaler) Patented multidose dry powder inhaler (DPI) used to deliver Formoterol Fumarate formulations (6 mcg and 12 mcg metered doses). Beneficial ownership held by Andi-Ventis Ltd., a joint venture between Medochemie Ltd. and MIAT SpA, with manufacturing in Limassol, Cyprus. Targeted at respiratory pharmaceutical manufacturers.
• ANDI-MED Nebulizing Chamber Innovative multipurpose nebulizer chamber for aerosol therapy with variable deposition characteristics adaptable to different respiratory pathologies and specific drugs to be nebulized. Worldwide patent rights owned by MIAT; developed by Med2000 R&D laboratory. Targeted at respiratory drug delivery developers and pharmaceutical manufacturers.

Quantifiable outcome

• 51 countries where MIAT sells its products
• +2 more outcomes

Segments4 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

23 partnerships are on record, tiered core and minor.

• Aminologics Co. LtdcoreStrategic or Co-development Partner · 20 October 2023Korean high-tech pharmaceutical company (part of SAM-OH Group) involved in API, unnatural amino acids, intermediates R&D and production. Co-exhibits with MIAT at CPHI events.
• LG Life Sciences LtdminorChannel Partner/ Reseller/ Distributor · 20 October 2023Listed partner for pharmaceutical ingredients supply.
• Fondazione IRCCS Istituto Nazionale dei TumoricoreStrategic or Co-development Partner · 4 June 2018Collaboration agreement for development of specific research projects including a Vitamin A derivative (s-4-oxo-HPR) as a novel non-toxic chemotherapeutic agent for cancer therapy. Non-clinical development program conducted with Laboratory of Preclinical Research (LARP) of University of Ferrara.
• SAM-OH Pharm Co. LtdcoreStrategic or Co-development Partner · 4 July 2016After over 30 years of business cooperation, MIAT and SAM-OH entered into a partnership where SAM-OH became shareholder in MIAT and MIAT invested similarly to enter as shareholder into SAM-OH Group. SAM-OH Pharm is a Korean high-tech pharmaceutical company involved in API, unnatural amino acids, intermediates R&D and production. Collaboration spans 40 years including shared exhibition booths at CPHI events.
• Nipro CorporationcoreChannel Partner/ Reseller/ Distributor · 4 October 2015During CPhI in Madrid, MIAT was appointed as worldwide distributor (outside Japan) of NP-CONTAINER, a high-technology multidose preservative-free container for ophthalmic formulations. Nipro is worldwide recognized as an innovative company in medical devices and hospital equipment.
• Med2000 S.r.l.coreTechnology or Integration · 4 November 2014Agreement with Med2000 for acquisition of patent rights for ANDI-MED nebulizing chamber. Long-standing business relationship with tight cooperation in R&D for respiratory drug delivery systems.
• LDO Laboratori Derivati Organici S.p.A.minorChannel Partner/ Reseller/ Distributor · 20 October 2013Listed partner for pharmaceutical intermediates.
• Gnosis S.p.A.minorChannel Partner/ Reseller/ Distributor · 20 October 2013Listed partner for pharmaceutical ingredients.
• Farmabios S.p.A.minorChannel Partner/ Reseller/ Distributor · 20 October 2013Listed partner for pharmaceutical ingredients.
• ACS Dobfar S.p.A.minorChannel Partner/ Reseller/ Distributor · 20 October 2013Listed partner for pharmaceutical ingredients.
• Biofer S.p.A.minorChannel Partner/ Reseller/ Distributor · 20 October 2013Listed partner for pharmaceutical ingredients.
• Glycores S.r.l.minorChannel Partner/ Reseller/ Distributor · 20 October 2013Listed partner for pharmaceutical ingredients.
• Glytech Inc.minorChannel Partner/ Reseller/ Distributor · 20 October 2013Listed partner (Japan) for pharmaceutical ingredients.
• Dae Woong LtdminorChannel Partner/ Reseller/ Distributor · 20 October 2013Listed partner (South Korea) for pharmaceutical ingredients.
• Raphas Co. LtdminorChannel Partner/ Reseller/ Distributor · 20 October 2013Listed partner (South Korea) for pharmaceutical ingredients.
• RStech CorporationminorChannel Partner/ Reseller/ Distributor · 20 October 2013Listed partner (South Korea) for HPLC columns and chromatographic analysis products.
• Sansho Co. LtdminorChannel Partner/ Reseller/ Distributor · 20 October 2013Listed partner (Japan) for pharmaceutical ingredients.
• Pharma Partners Co. LtdminorChannel Partner/ Reseller/ Distributor · 20 October 2013Listed partner (Japan) for pharmaceutical ingredients.
• Laboratorio Centralizzato di Ricerca Preclinica (LARP)coreStrategic or Co-development Partner · 20 October 2013University of Ferrara's Laboratory for preclinical research collaborating on cancer therapeutic compound development (s-4-oxo-HPR).
• Università di Milano (Dipartimento di Chimica Organica e Industriale)coreStrategic or Co-development Partner · 20 October 2013Academic partner through Pharmafilm spin-off for development of adhesive hydrogel plasters.
• Pharmafilm s.r.l.coreStrategic or Co-development Partner · 4 April 2013Agreement between MIAT S.p.A. and Pharmafilm s.r.l. (spin-off of the University of Milan) for technical, scientific and regulatory development of plasters based on adhesive hydrogels for muscle-skeletal pathologies and pain management. Production by Oishi Koseido.
• Andi-Ventis LtdcoreStrategic or Co-development Partner · 4 January 2013Joint-venture between Medochemie Ltd. and MIAT SpA for development and production of dry powder inhaler formulations. Dedicated plant in Limassol, Cyprus producing corticosteroids and LABAs for respiratory diseases using MIAT-Haler device.
• Oishi Koseido Co. LtdcoreStrategic or Co-development Partner · 4 December 2012Global agreement for development and promotion of Oishi plasters in international markets. Oishi has over 100 years history with 50+ years experience in plasters and gel patches production under GMP procedures. Manufacturing plant in Tosu City, Saga (Kyushu), Japan.

Scale indicators5 records

Recent moves7 records

Expansion highlights5 records

Broad incumbents

• PHOENIX Pharmahandel: Pan-European pharmaceutical wholesale and distribution group headquartered in Germany; comparable as a large-scale pharma wholesaler whose model (GDP-compliant pan-European pharma distribution) sets the benchmark against which MIAT's niche Italian export-import trading is sized.
• AptarGroup: Global leader in drug delivery systems including metered-dose and dry powder inhalers as well as dispensers for ophthalmics; comparable to MIAT's medical-device business unit spanning MIAT-Haler DPI, ANDI-MED nebulizers, and NP-CONTAINER ophthalmic packaging.
• Nipro Corporation: Major Japanese medical device and pharma packaging company; MIAT is its worldwide ex-Japan distributor for the NP-CONTAINER, making Nipro a directly adjacent counterparty with overlapping exposure to ophthalmic packaging and medical devices.

Direct peers

• Olon S.p.A. Italian API manufacturer (one of the largest globally) supplying generic APIs to pharma companies; directly comparable as an Italian-headquartered API/fermentation specialist serving international pharma buyers.
• SAM-OH Pharm: Korean API, intermediate, and amino-acid producer that is both MIAT's cross-shareholder and exhibitor partner at CPHI; highly comparable API/product portfolio and joint go-to-market model in pharma trading.
• Medochemie: Cyprus-headquartered multinational generic pharmaceutical manufacturer with API and finished-dose franchises; directly comparable to MIAT as the JV partner in Andi-Ventis Ltd., sharing exposure to European pharma distribution and respiratory/steroid formulations.
• LDO Laboratori Derivati Organici S.p.A. Italian producer of pharmaceutical-grade intermediates (sterols, bile acids, hormones) for API makers; a listed MIAT partner with highly overlapping product categories (intermediates/APIs) and shared Italian base serving international pharma customers.
• ACS Dobfar S.p.A. Italian API manufacturer specializing in sterile cephalosporins and other antibiotics; directly comparable as an Italian-headquartered API supplier with international export reach to MIAT's same customer base.
• Farmabios S.p.A. Italian-based manufacturer of APIs, intermediates, and excipients for the pharmaceutical industry; a listed MIAT partner with overlapping product mix in APIs and intermediates sold to pharma customers.
• Aminologics Co., Ltd. Korean manufacturer of unnatural amino acids, APIs, and intermediates (part of SAM-OH Group); directly comparable as a Korean supplier partner co-exhibiting with MIAT at CPHI and serving the same pharma R&D and manufacturing customers.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/miat-s-p-a

Compliance6 records

Revenue estimate

Valuation estimate

Number of profiles

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about MIAT